Placenta Growth Factor and Sflt-1 As Biomarkers in Ischemic Heart Disease and Heart Failure: A Review

References

• Benjamin EJ , ViraniSS, CallawayCWet al. Heart disease and stroke statistics – 2018 update: a report from the American Heart Association. Circulation137(12), e67–e492 (2018).
   PubMed Web of Science ®Google Scholar
• Van Berlo JH , MolkentinJD. An emerging consensus on cardiac regeneration. Nat. Med.20(12), 1386–1393 (2014).
   PubMed Web of Science ®Google Scholar
• Cai CL , MolkentinJD. The elusive progenitor cell in cardiac regeneration: slip slidin’ away. Circ. Res.120(2), 400–406 (2017).
   PubMed Web of Science ®Google Scholar
• Morrow DA , d e LemosJA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation115(8), 949–952 (2007).
   PubMed Web of Science ®Google Scholar
• Hlatky MA , GreenlandP, ArnettDKet al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation119(17), 2408–2416 (2009).
   PubMedGoogle Scholar
• McCarthy CP , McEvoyJW, JanuzziJL Jr. Biomarkers in stable coronary artery disease. Am. Heart J.196, 82–96 (2018).
   PubMed Web of Science ®Google Scholar
• Ibrahim NE , GagginHK, KonstamMA, JanuzziJL Jr. Established and emerging roles of biomarkers in heart failure clinical trials. Circ. Heart Fail9(9), pii:e002528 (2016).
   PubMed Web of Science ®Google Scholar
• Dewerchin M , CarmelietP. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb. Perspect. Med.2(8), pii:a011056 (2012).
   PubMed Web of Science ®Google Scholar
• Maglione D , GuerrieroV, VigliettoG, Delli-BoviP, PersicoMG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl Acad. Sci. USA88(20), 9267–9271 (1991).
   PubMed Web of Science ®Google Scholar
• Persico MG , VincentiV, DipalmaT. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr. Top. Microbiol. Immunol.237, 31–40 (1999).
   PubMed Web of Science ®Google Scholar
• De Falco S . The discovery of placenta growth factor and its biological activity. Exp. Mol. Med.44(1), 1–9 (2012).
   PubMed Web of Science ®Google Scholar
• Failla CM , CarboM, MoreaV. Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor receptor-1. Int. J. Mol. Sci.19(5), pii:E1306 (2018).
   Web of Science ®Google Scholar
• Autiero M , WaltenbergerJ, CommuniDet al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med.9(7), 936–943 (2003).
   PubMed Web of Science ®Google Scholar
• Kendall RL , ThomasKA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA90(22), 10705–10709 (1993).
   PubMed Web of Science ®Google Scholar
• Kendall RL , WangG, ThomasKA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun.226(2), 324–328 (1996).
   PubMed Web of Science ®Google Scholar
• Tidwell SC , HoHN, ChiuWH, TorryRJ, TorryDS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am. J. Obstet. Gynecol.184(6), 1267–1272 (2001).
   PubMed Web of Science ®Google Scholar
• Torry DS , WangHS, WangTH, CaudleMR, TorryRJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am. J. Obstet. Gynecol.179(6), 1539–1544 (1998).
   PubMed Web of Science ®Google Scholar
• Wolf M , ShahA, LamCet al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am. J. Obstet. Gynecol.193(1), 16–22 (2005).
   PubMed Web of Science ®Google Scholar
• Levine RJ , MaynardSE, QianCet al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med.350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• Ahmad S , AhmedA. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res.95(9), 884–891 (2004).
   PubMed Web of Science ®Google Scholar
• Caillon H , TardifC, DumontetE, WinerN, MassonD. Evaluation of sFlt-1/PlGF ratio for predicting and improving clinical management of pre-eclampsia: experience in a specialized perinatal care center. Ann. Lab. Med.38(2), 95–101 (2018).
   PubMed Web of Science ®Google Scholar
• Chau K , HennessyA, MakrisA. Placental growth factor and pre-eclampsia. J. Hum. Hypertens31(12), 782–786 (2017).
   PubMed Web of Science ®Google Scholar
• Behrens I , BasitS, LykkeJAet al. Hypertensive disorders of pregnancy and peripartum cardiomyopathy: a nationwide cohort study. PLoS ONE14(2), e0211857 (2019).
   PubMed Web of Science ®Google Scholar
• Patten IS , RanaS, ShahulSet al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature485(7398), 333–338 (2012).
   PubMed Web of Science ®Google Scholar
• Llurba E , SanchezO, FerrerQet al. Maternal and foetal angiogenic imbalance in congenital heart defects. Eur. Heart J.35(11), 701–707 (2014).
   PubMed Web of Science ®Google Scholar
• De Falco S , GiganteB, PersicoMG. Structure and function of placental growth factor. Trends Cardiovasc. Med.12(6), 241–246 (2002).
   PubMed Web of Science ®Google Scholar
• Carmeliet P , MoonsL, LuttunAet al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med7(5), 575–583 (2001).
   PubMed Web of Science ®Google Scholar
• Luttun A , TjwaM, CarmelietP. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. N. Y. Acad. Sci.979, 80–93 (2002).
   PubMed Web of Science ®Google Scholar
• Oura H , BertonciniJ, VelascoP, BrownLF, CarmelietP, DetmarM. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood101(2), 560–567 (2003).
   PubMed Web of Science ®Google Scholar
• Iwasaki H , KawamotoA, TjwaMet al. PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS ONE6(9), e24872 (2011).
   PubMed Web of Science ®Google Scholar
• Gigante B , TarsitanoM, CiminiV, DeFalco S, PersicoMG. Placenta growth factor is not required for exercise-induced angiogenesis. Angiogenesis7(3), 277–284 (2004).
   PubMedGoogle Scholar
• Accornero F , MolkentinJD. Placental growth factor as a protective paracrine effector in the heart. Trends Cardiovasc Med21(8), 220–224 (2011).
   PubMed Web of Science ®Google Scholar
• Accornero F , Van BerloJH, BenardMJ, LorenzJN, CarmelietP, MolkentinJD. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res109(3), 272–280 (2011).
   PubMed Web of Science ®Google Scholar
• Wu M , PokreiszP, SwinnenMet al. Sustained placental growth factor-2 treatment does not aggravate advanced atherosclerosis in ischemic cardiomyopathy. J. Cardiovasc. Transl. Res.10(4), 348–358 (2017).
   PubMed Web of Science ®Google Scholar
• Khurana R , MoonsL, ShafiSet al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation111(21), 2828–2836 (2005).
   PubMed Web of Science ®Google Scholar
• Roncal C , BuysschaertI, GerdesNet al. Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc. Res.86(1), 29–36 (2010).
   PubMed Web of Science ®Google Scholar
• McGraw AP , BagleyJ, ChenWSet al. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J. Am. Heart Assoc.2(1), e000018 (2013).
   PubMed Web of Science ®Google Scholar
• Torry RJ , TomanekRJ, ZhengW, MillerSJ, LabarrereCA, TorryDS. Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J. Heart Lung Transplant.28(2), 183–190 (2009).
   PubMed Web of Science ®Google Scholar
• Sands M , HowellK, CostelloCM, McLoughlinP. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir. Res.12, 17 (2011).
   PubMed Web of Science ®Google Scholar
• Kelly BD , HackettSF, HirotaKet al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res.93(11), 1074–1081 (2003).
   PubMed Web of Science ®Google Scholar
• Yonekura H , SakuraiS, LiuXet al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J. Biol. Chem.274(49), 35172–35178 (1999).
   PubMed Web of Science ®Google Scholar
• Loboda A , JazwaA, JozkowiczA, MolemaG, DulakJ. Angiogenic transcriptome of human microvascular endothelial cells: effect of hypoxia, modulation by atorvastatin. Vascul. Pharmacol.44(4), 206–214 (2006).
   PubMed Web of Science ®Google Scholar
• Torry DS , HinrichsM, TorryRJ. Determinants of placental vascularity. Am. J. Reprod. Immunol.51(4), 257–268 (2004).
   PubMed Web of Science ®Google Scholar
• Gleadle JM , EbertBL, FirthJD, RatcliffePJ. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am. J. Physiol.268(6 Pt 1), C1362–1368 (1995).
   PubMedGoogle Scholar
• Luttun A , TjwaM, MoonsLet al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med.8(8), 831–840 (2002).
   PubMed Web of Science ®Google Scholar
• Takeda Y , UemuraS, IwamaHet al. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ. J.73(9), 1674–1682 (2009).
   PubMed Web of Science ®Google Scholar
• Liu X , ClausP, WuMet al. Placental growth factor increases regional myocardial blood flow and contractile function in chronic myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol.304(6), H885–894 (2013).
   PubMed Web of Science ®Google Scholar
• Wu M , ClausP, Vanden DriesscheNet al. Placental growth factor 2 – a potential therapeutic strategy for chronic myocardial ischemia. Int. J. Cardiol.203, 534–542 (2016).
   PubMed Web of Science ®Google Scholar
• Kolakowski S Jr , BerryMF, AtluriPet al. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J. Card. Surg.21(6), 559–564 (2006).
   PubMed Web of Science ®Google Scholar
• Binsalamah ZM , PaulA, KhanAA, PrakashS, Shum-TimD. Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model. Int. J. Nanomedicine6, 2667–2678 (2011).
   PubMed Web of Science ®Google Scholar
• Luo L , ChenB, HuangYet al. Cardioprotective activity of placental growth factor combined with oral supplementation of L-arginine in a rat model of acute myocardial infarction. Drug Design Dev. Ther.10, 3483–3492 (2016).
   PubMedGoogle Scholar
• Roncal C , BuysschaertI, ChorianopoulosEet al. Beneficial effects of prolonged systemic administration of PlGF on late outcome of post-ischaemic myocardial performance. J. Pathol.216(2), 236–244 (2008).
   PubMed Web of Science ®Google Scholar
• Bearzi C , GargioliC, BaciDet al. PlGF-MMP9-engineered iPS cells supported on a PEG-fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium. Cell Death Dis.5(1), e1053 (2014).
   PubMedGoogle Scholar
• Moriya J . Critical roles of inflammation in atherosclerosis. J. Cardiol.73(1), 22–27 (2018).
   PubMed Web of Science ®Google Scholar
• Pilarczyk K , SattlerKJ, GaliliOet al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis196(1), 333–340 (2008).
   PubMed Web of Science ®Google Scholar
• Kim SY , LeeSH, ParkSet al. Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1, and the severity of coronary artery disease. Angiology62(2), 176–183 (2011).
   PubMed Web of Science ®Google Scholar
• Chung NA , LydakisC, BelgoreF, Li-Saw-HeeFL, BlannAD, LipGY. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart89(12), 1411–1415 (2003).
   PubMed Web of Science ®Google Scholar
• Onoue K , UemuraS, TakedaYet al. Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation120(24), 2470–2477 (2009).
   PubMed Web of Science ®Google Scholar
• Hamsten A , WalldiusG, SzamosiA, DahlenG, DeFaire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation73(6), 1097–1110 (1986).
   PubMed Web of Science ®Google Scholar
• Kodama Y , KittaY, NakamuraTet al. Atorvastatin increases plasma soluble fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J. Am. Coll. Cardiol.48(1), 43–50 (2006).
   PubMed Web of Science ®Google Scholar
• Kapur NK , HeffernanKS, YunisAAet al. Elevated soluble fms-like tyrosine kinase-1 levels in acute coronary occlusion. Arterioscler. Thromb. Vasc. Biol.31(2), 443–450 (2011).
   PubMed Web of Science ®Google Scholar
• Fong SW , FewLL, SeeToo WCet al. Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease. BMC Res. Notes8, 679 (2015).
   PubMedGoogle Scholar
• Apple FS , PearceLA, ChungA, LerR, MurakamiMM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem.53(5), 874–881 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang M , LuS, WuXet al. Multimarker approach for the prediction of cardiovascular events in patients with mild to moderate coronary artery lesions. A 3-year follow-up study. Int. Heart J.53(2), 85–90 (2012).
   PubMed Web of Science ®Google Scholar
• Lenderink T , HeeschenC, FichtlschererSet al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J. Am. Coll. Cardiol.47(2), 307–311 (2006).
   PubMed Web of Science ®Google Scholar
• Cassidy A , ChiuveSE, MansonJE, RexrodeKM, GirmanCJ, RimmEB. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler. Thromb. Vasc. Biol.29(1), 134–139 (2009).
   PubMed Web of Science ®Google Scholar
• Markovic M , IgnjatovicS, DajakM, Majkic-SinghN. Utility of placental growth factor for prediction of 30-day adverse event in emergency department population with non-ST elevation acute coronary syndrome. Clin. Lab.56(5-6), 215–222 (2010).
   PubMed Web of Science ®Google Scholar
• Bui AH , BonacaMP, SabatineMSet al. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Thrombosis Thrombolysis34(2), 222–228 (2012).
   PubMed Web of Science ®Google Scholar
• Iwama H , UemuraS, NayaNet al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J. Am. Coll. Cardiol.47(8), 1559–1567 (2006).
   PubMed Web of Science ®Google Scholar
• Onoue K , UemuraS, TakedaYet al. Usefulness of soluble fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am. J. Cardiol.104(11), 1478–1483 (2009).
   PubMed Web of Science ®Google Scholar
• Hochholzer W , ReichlinT, StelzigCet al. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur. Heart J.32(3), 326–335 (2011).
   PubMed Web of Science ®Google Scholar
• Kameda R , Yamaoka-TojoM, MakinoAet al. Soluble fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation. Int. Heart J.54(3), 133–139 (2013).
   PubMed Web of Science ®Google Scholar
• Matsumoto T , UemuraS, TakedaYet al. An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease. Intern. Med.52(10), 1019–1027 (2013).
   PubMed Web of Science ®Google Scholar
• Sinning C , SchnabelRB, ZellerTet al. Prognostic use of soluble fms-like tyrosine kinase-1 and placental growth factor in patients with coronary artery disease. Biomark. Med.10(1), 95–106 (2016).
   PubMed Web of Science ®Google Scholar
• Sun Z , ShenY, LuLet al. Increased serum level of soluble vascular endothelial growth factor receptor-1 is associated with poor coronary collateralization in patients with stable coronary artery disease. Circ. J.78(5), 1191–1196 (2014).
   PubMed Web of Science ®Google Scholar
• Matsui M , UemuraS, TakedaYet al. Placental growth factor as a predictor of cardiovascular events in patients with CKD from the NARA-CKD study. J. Am. Soc. Nephrol.26(11), 2871–2881 (2015).
   PubMed Web of Science ®Google Scholar
• Zheng SL , ChanFT, NabeebaccusAAet al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart104(5), 407–415 (2018).
   PubMed Web of Science ®Google Scholar
• De Boer RA , NayorM, DefilippiCRet al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol.3(3), 215–224 (2018).
   PubMed Web of Science ®Google Scholar
• Chow SL , MaiselAS, AnandIet al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation135(22), e1054–e1091 (2017).
   PubMed Web of Science ®Google Scholar
• Heil B , TangWH. Biomarkers: their potential in the diagnosis and treatment of heart failure. Cleve Clin. J. Med.82(12 Suppl. 2), S28–S35 (2015).
   PubMedGoogle Scholar
• Liquori ME , ChristensonRH, CollinsonPO, DefilippiCR. Cardiac biomarkers in heart failure. Clin. Biochem.47(6), 327–337 (2014).
   PubMed Web of Science ®Google Scholar
• Cohen-Solal A , LaribiS, IshiharaSet al. Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Arch. Cardiovasc. Dis.108(1), 64–74 (2015).
   PubMed Web of Science ®Google Scholar
• Jungbauer CG , RiedlingerJ, BlockDet al. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark. Med.8(6), 777–789 (2014).
   PubMed Web of Science ®Google Scholar
• Shirazi LF , BissettJ, RomeoF, MehtaJL. Role of inflammation in heart failure. Curr. Atheroscler. Rep.19(6), 27 (2017).
   PubMed Web of Science ®Google Scholar
• Paulus WJ , TschopeC. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. College Cardiol.62(4), 263–271 (2013).
   PubMed Web of Science ®Google Scholar
• Hartupee J , MannDL. Positioning of inflammatory biomarkers in the heart failure landscape. J. Cardiovasc. Transl. Res.6(4), 485–492 (2013).
   PubMed Web of Science ®Google Scholar
• Ueland T , GullestadL, NymoSH, YndestadA, AukrustP, AskevoldET. Inflammatory cytokines as biomarkers in heart failure. Clin. Chim. Acta443, 71–77 (2015).
   PubMed Web of Science ®Google Scholar
• Nakamura T , FunayamaH, KuboNet al. Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int. J. Cardiol.131(2), 186–191 (2009).
   PubMed Web of Science ®Google Scholar
• Hammadah M , GeorgiopoulouVV, KalogeropoulosAPet al. Elevated soluble fms-like tyrosine kinase-1 and placental-like growth factor levels are associated with development and mortality risk in heart failure. Circ. Heart Fail.9(1), e002115 (2016).
   PubMed Web of Science ®Google Scholar
• Ky B , FrenchB, RuparelKet al. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J. Am. Coll. Cardiol.58(4), 386–394 (2011).
   PubMed Web of Science ®Google Scholar
• Gruson D , HermansMP, FerracinB, AhnSA, RousseauMF. Sflt-1 in heart failure: relation with disease severity and biomarkers. Scand. J. Clin. Lab. Invest.76(5), 411–416 (2016).
   PubMed Web of Science ®Google Scholar
• Gmeiner M , ZimpferD, HolfeldJet al. Improvement of cardiac function in the failing rat heart after transfer of skeletal myoblasts engineered to overexpress placental growth factor. J. Thorac. Cardiovasc. Surg.141(5), 1238–1245 (2011).
   PubMed Web of Science ®Google Scholar
• Zimna A , WiernickiB, KolanowskiTet al. Biological and pro-angiogenic properties of genetically modified human primary myoblasts overexpressing placental growth factor in in vitro and in vivo studies. Arch. Immunol. Ther. Exp. (Warsz.)66(2), 145–159 (2018).
   PubMed Web of Science ®Google Scholar
• Kaza E , AblasserK, PoutiasDet al. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc. Res.89(2), 410–418 (2011).
   PubMed Web of Science ®Google Scholar
• Seno A , TakedaY, MatsuiMet al. Suppressed production of soluble fms-like tyrosine kinase-1 contributes to myocardial remodeling and heart failure. Hypertension68(3), 678–687 (2016).
   PubMed Web of Science ®Google Scholar
• Foglia MJ , PossKD. Building and re-building the heart by cardiomyocyte proliferation. Development143(5), 729–740 (2016).
   PubMed Web of Science ®Google Scholar
• Karra R , PossKD. Redirecting cardiac growth mechanisms for therapeutic regeneration. J. Clin. Invest.127(2), 427–436 (2017).
   PubMed Web of Science ®Google Scholar
• Senyo SE , LeeRT, KuhnB. Cardiac regeneration based on mechanisms of cardiomyocyte proliferation and differentiation. Stem Cell Res.13(3), 532–541 (2014).
   PubMed Web of Science ®Google Scholar
• Uygur A , LeeRT. Mechanisms of cardiac regeneration. Dev. Cell.36(4), 362–374 (2016).
   PubMed Web of Science ®Google Scholar
• Kamo T , AkazawaH, KomuroI. Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circulation Research117(1), 89–98 (2015).
   PubMed Web of Science ®Google Scholar
• Segers VFM , BrutsaertDL, DeKeulenaer GW. Cardiac remodeling: endothelial cells have more to say than just NO. Front. Physiol.9, 382 (2018).
   PubMed Web of Science ®Google Scholar
• Jaba IM , ZhuangZW, LiNet al. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J. Clin. Invest.123(4), 1718–1731 (2013).
   PubMed Web of Science ®Google Scholar
• Yang F , JinC, JiangYJ, LiJ, DiY, FuDL. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert. Rev. Anticancer Ther.11(4), 541–549 (2011).
   PubMed Web of Science ®Google Scholar
• Di Marco GS , KentrupD, ReuterSet al. Soluble Flt-1 links microvascular disease with heart failure in CKD. Basic Res. Cardiol.110(3), 30 (2015).
   PubMed Web of Science ®Google Scholar
• Maynard SE , MinJY, MerchanJet al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest.111(5), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Ohanyan V , SisakianH, PeketiP, ParikhA, ChilianW. A chicken and egg conundrum: coronary microvascular dysfunction and heart failure with preserved ejection fraction. Am. J. Physiol. Heart Circ. Physiol.314(6), H1262–H1263 (2018).
   PubMed Web of Science ®Google Scholar
• Shah SJ , KitzmanDW, BorlaugBAet al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation134(1), 73–90 (2016).
   PubMed Web of Science ®Google Scholar
• Franssen C , ChenS, UngerAet al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail.4(4), 312–324 (2016).
   PubMed Web of Science ®Google Scholar
• Dryer K , GajjarM, NarangNet al. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am. J. Physiol. Heart Circ. Physiol.314(5), H1033–H1042 (2018).
   PubMed Web of Science ®Google Scholar
• Searle J , MockelM, GwoscSet al. Heparin strongly induces soluble fms-like tyrosine kinase 1 release in vivo and in vitro – brief report. Arterioscler. Thromb. Vasc. Biol.31(12), 2972–2974 (2011).
   PubMed Web of Science ®Google Scholar
• Lavainne F , MeffrayE, PepperRJet al. Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. Nephrol. Dial. Transplant.29(6), 1225–1231 (2014).
   PubMed Web of Science ®Google Scholar
• Kylhammar D , HesselstrandR, NielsenS, ScheeleC, RadegranG. Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. Scand. J. Rheumatol.47(4), 319–324 (2018).
   PubMed Web of Science ®Google Scholar